• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RCE
Click for more information
8.14% 46.5¢

RECCE PHARMACEUTICALS LTD - Announcements

Market Cap $118.1M  ! watchlist Created with Sketch. Add to my watchlist

Recce Pharmaceuticals Ltd is an Australia-based company engaged in the development and... Recce Pharmaceuticals Ltd is an Australia-based company engaged in the development and commercialization of a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The Company's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses. All RECCE compounds are water soluble at all pH levels in their liquid form.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
RCE USA Patent Granted for Recce's AntibioticsPRICE SENSITIVE14/03/19
RCE Half Yearly Report and AccountsPRICE SENSITIVE27/02/19
RCE Recce Successfully Raises $1.8 million via PlacementPRICE SENSITIVE08/02/19
RCE Trading HaltPRICE SENSITIVE06/02/19
RCE Appendix 4C and commentaryPRICE SENSITIVE31/01/19
RCE R&D Incentive Rebate ReceivedPRICE SENSITIVE31/01/19
RCE Funding UpdatePRICE SENSITIVE18/01/19
RCE Funding UpdatePRICE SENSITIVE18/12/18
RCE Funding UpdatePRICE SENSITIVE23/11/18
RCE Appendix 4C and commentaryPRICE SENSITIVE01/11/18
RCE R&D Incentive Rebate ReceivedPRICE SENSITIVE02/10/18
RCE Funding UpdatePRICE SENSITIVE13/09/18
RCE Appendix 4E - Preliminary Final ReportPRICE SENSITIVE31/08/18
RCE Key Australian Patent for Recce's Broad-Spectrum AntibioticsPRICE SENSITIVE31/07/18
RCE Appendix 4C and commentaryPRICE SENSITIVE30/07/18
RCE Update on Progress of Broad Spectrum Antibiotic RECCE 327PRICE SENSITIVE17/07/18 download Created with Sketch. 180.48KB
RCE Update on meeting with US FDAPRICE SENSITIVE05/06/18 download Created with Sketch. 520.35KB
RCE Appendix 4C and commentaryPRICE SENSITIVE30/04/18
RCE Additional AU$861,590 R&D Tax Incentive Rebate ReceivedPRICE SENSITIVE23/04/18
RCE Recce Half Yearly Report and Appendix 4DPRICE SENSITIVE28/02/18
RCE Data Submission & Further Communication Request with US FDAPRICE SENSITIVE15/02/18
RCE Appendix 4C and commentaryPRICE SENSITIVE31/01/18
RCE AusIndustry Awards Recce Financial SupportPRICE SENSITIVE15/01/18
RCE US FDA Grants Qualified Infectious Disease Product DesignatiPRICE SENSITIVE16/11/17
RCE Trading HaltPRICE SENSITIVE14/11/17
RCE Appendix 4C - quarterlyPRICE SENSITIVE31/10/17
RCE Recce Launches Share Purchase PlanPRICE SENSITIVE27/09/17
RCE Response to ASX Price QueryPRICE SENSITIVE18/09/17
RCE Recce Confirms Pre-IND Data Submission to US FDAPRICE SENSITIVE07/09/17
RCE Appendix 4E and Financial ReportPRICE SENSITIVE01/09/17
RCE Appendix 4C - quarterlyPRICE SENSITIVE31/07/17
RCE Recce Confirms Delivery by Intravenous DripPRICE SENSITIVE31/07/17
RCE Recce achieves milestone with volume productionPRICE SENSITIVE20/07/17
RCE Recce constructs automated manufacturing facility to supportPRICE SENSITIVE22/06/17
RCE Recce secures up to A$6.05 million investment agreement withPRICE SENSITIVE16/06/17
RCE Recce moves closer to clinical study applicationPRICE SENSITIVE19/05/17
RCE Appendix 4C - quarterlyPRICE SENSITIVE28/04/17
RCE Operational UpdatePRICE SENSITIVE10/04/17
RCE Data from large animal study shows RECCE 327 well toleratedPRICE SENSITIVE27/03/17
RCE Appendix 4D and Interim Financial StatementsPRICE SENSITIVE28/02/17
RCE Microscopy Images of its Synthetic Antibiotic in Action DestPRICE SENSITIVE24/02/17
RCE Recce to suspend anti-cancer programPRICE SENSITIVE23/02/17
RCE Operational Update and Quarterly Cash FlowPRICE SENSITIVE30/01/17
RCE Response to ASX Price QueryPRICE SENSITIVE18/01/17
RCE Lead compound reduces illness in mice infected by E.coliPRICE SENSITIVE18/01/17
RCE Trading HaltPRICE SENSITIVE16/01/17
RCE Encouraging anti-viral activity for lead compound RECCE 327PRICE SENSITIVE20/12/16
RCE Pre-clinical toxicology and efficacy testing-RCE.AX PRICE SENSITIVE02/11/16
RCE Operational Update and Quarterly Cash Flow-RCE.AX PRICE SENSITIVE31/10/16
RCE Appendix 4E and Financial Report-RCE.AX PRICE SENSITIVE28/08/16
RCE Appendix 4E and Financial Report-RCE.AX PRICE SENSITIVE25/08/16
RCE Dose Ranging in Mice - Repeated Success-RCE.AX PRICE SENSITIVE15/08/16
RCE Appendix 4C - quarterly-RCE.AX PRICE SENSITIVE29/07/16
RCE Successful Test Results for Genetic Toxicity-RCE.AX PRICE SENSITIVE20/07/16
RCE Anti-viral Activity-RCE.AX PRICE SENSITIVE13/07/16
RCE Update on Testing Schedules-RCE.AX PRICE SENSITIVE21/06/16
RCE Encouraging Results from Safety Test-RCE.AX PRICE SENSITIVE25/05/16
RCE Recce - The Way Forward-RCE.AX PRICE SENSITIVE03/05/16
RCE Appendix 4C - quarterly-RCE.AX PRICE SENSITIVE27/04/16
RCE Progress Update-RCE.AX PRICE SENSITIVE11/04/16
RCE International Trade Mark Registrations-RCE.AX PRICE SENSITIVE06/04/16
RCE Anti-cancer ActivitiesPRICE SENSITIVE14/03/16
RCE Appendix 4D and Half Year Financial StatementsPRICE SENSITIVE26/02/16
RCE Efficacy without ToxicityPRICE SENSITIVE02/02/16
RCE Appendix 4C - quarterlyPRICE SENSITIVE29/01/16
RCE RECCE Antibiotic kills TB and GonorrhoeaPRICE SENSITIVE27/01/16
RCE Additional Patent DevelopmentsPRICE SENSITIVE15/01/16
RCE Patent Granted in ChinaPRICE SENSITIVE15/01/16
RCE Admission to Official ListPRICE SENSITIVE13/01/16
RCE USA Patent Granted for Recce's Antibiotics
14/03/19PRICE SENSITIVE
RCE Half Yearly Report and Accounts
27/02/19PRICE SENSITIVE
RCE Recce Successfully Raises $1.8 million via Placement
08/02/19PRICE SENSITIVE
RCE Trading Halt
06/02/19PRICE SENSITIVE
RCE Appendix 4C and commentary
31/01/19PRICE SENSITIVE
RCE R&D Incentive Rebate Received
31/01/19PRICE SENSITIVE
RCE Funding Update
18/01/19PRICE SENSITIVE
RCE Funding Update
18/12/18PRICE SENSITIVE
RCE Funding Update
23/11/18PRICE SENSITIVE
RCE Appendix 4C and commentary
01/11/18PRICE SENSITIVE
RCE R&D Incentive Rebate Received
02/10/18PRICE SENSITIVE
RCE Funding Update
13/09/18PRICE SENSITIVE
RCE Appendix 4E - Preliminary Final Report
31/08/18PRICE SENSITIVE
RCE Key Australian Patent for Recce's Broad-Spectrum Antibiotics
31/07/18PRICE SENSITIVE
RCE Appendix 4C and commentary
30/07/18PRICE SENSITIVE
RCE Update on Progress of Broad Spectrum Antibiotic RECCE 327
17/07/18PRICE SENSITIVE download Created with Sketch. 180.48KB
RCE Update on meeting with US FDA
05/06/18PRICE SENSITIVE download Created with Sketch. 520.35KB
RCE Appendix 4C and commentary
30/04/18PRICE SENSITIVE
RCE Additional AU$861,590 R&D Tax Incentive Rebate Received
23/04/18PRICE SENSITIVE
RCE Recce Half Yearly Report and Appendix 4D
28/02/18PRICE SENSITIVE
RCE Data Submission & Further Communication Request with US FDA
15/02/18PRICE SENSITIVE
RCE Appendix 4C and commentary
31/01/18PRICE SENSITIVE
RCE AusIndustry Awards Recce Financial Support
15/01/18PRICE SENSITIVE
RCE US FDA Grants Qualified Infectious Disease Product Designati
16/11/17PRICE SENSITIVE
RCE Trading Halt
14/11/17PRICE SENSITIVE
RCE Appendix 4C - quarterly
31/10/17PRICE SENSITIVE
RCE Recce Launches Share Purchase Plan
27/09/17PRICE SENSITIVE
RCE Response to ASX Price Query
18/09/17PRICE SENSITIVE
RCE Recce Confirms Pre-IND Data Submission to US FDA
07/09/17PRICE SENSITIVE
RCE Appendix 4E and Financial Report
01/09/17PRICE SENSITIVE
RCE Appendix 4C - quarterly
31/07/17PRICE SENSITIVE
RCE Recce Confirms Delivery by Intravenous Drip
31/07/17PRICE SENSITIVE
RCE Recce achieves milestone with volume production
20/07/17PRICE SENSITIVE
RCE Recce constructs automated manufacturing facility to support
22/06/17PRICE SENSITIVE
RCE Recce secures up to A$6.05 million investment agreement with
16/06/17PRICE SENSITIVE
RCE Recce moves closer to clinical study application
19/05/17PRICE SENSITIVE
RCE Appendix 4C - quarterly
28/04/17PRICE SENSITIVE
RCE Operational Update
10/04/17PRICE SENSITIVE
RCE Data from large animal study shows RECCE 327 well tolerated
27/03/17PRICE SENSITIVE
RCE Appendix 4D and Interim Financial Statements
28/02/17PRICE SENSITIVE
RCE Microscopy Images of its Synthetic Antibiotic in Action Dest
24/02/17PRICE SENSITIVE
RCE Recce to suspend anti-cancer program
23/02/17PRICE SENSITIVE
RCE Operational Update and Quarterly Cash Flow
30/01/17PRICE SENSITIVE
RCE Response to ASX Price Query
18/01/17PRICE SENSITIVE
RCE Lead compound reduces illness in mice infected by E.coli
18/01/17PRICE SENSITIVE
RCE Trading Halt
16/01/17PRICE SENSITIVE
RCE Encouraging anti-viral activity for lead compound RECCE 327
20/12/16PRICE SENSITIVE
RCE Pre-clinical toxicology and efficacy testing-RCE.AX
02/11/16PRICE SENSITIVE
RCE Operational Update and Quarterly Cash Flow-RCE.AX
31/10/16PRICE SENSITIVE
RCE Appendix 4E and Financial Report-RCE.AX
28/08/16PRICE SENSITIVE
RCE Appendix 4E and Financial Report-RCE.AX
25/08/16PRICE SENSITIVE
RCE Dose Ranging in Mice - Repeated Success-RCE.AX
15/08/16PRICE SENSITIVE
RCE Appendix 4C - quarterly-RCE.AX
29/07/16PRICE SENSITIVE
RCE Successful Test Results for Genetic Toxicity-RCE.AX
20/07/16PRICE SENSITIVE
RCE Anti-viral Activity-RCE.AX
13/07/16PRICE SENSITIVE
RCE Update on Testing Schedules-RCE.AX
21/06/16PRICE SENSITIVE
RCE Encouraging Results from Safety Test-RCE.AX
25/05/16PRICE SENSITIVE
RCE Recce - The Way Forward-RCE.AX
03/05/16PRICE SENSITIVE
RCE Appendix 4C - quarterly-RCE.AX
27/04/16PRICE SENSITIVE
RCE Progress Update-RCE.AX
11/04/16PRICE SENSITIVE
RCE International Trade Mark Registrations-RCE.AX
06/04/16PRICE SENSITIVE
RCE Anti-cancer Activities
14/03/16PRICE SENSITIVE
RCE Appendix 4D and Half Year Financial Statements
26/02/16PRICE SENSITIVE
RCE Efficacy without Toxicity
02/02/16PRICE SENSITIVE
RCE Appendix 4C - quarterly
29/01/16PRICE SENSITIVE
RCE RECCE Antibiotic kills TB and Gonorrhoea
27/01/16PRICE SENSITIVE
RCE Additional Patent Developments
15/01/16PRICE SENSITIVE
RCE Patent Granted in China
15/01/16PRICE SENSITIVE
RCE Admission to Official List
13/01/16PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
46.5¢ 		Change
0.035(8.14%) 		Mkt cap ! $118.1M
Open High Low Value Volume
43.0¢ 46.5¢ 43.0¢ $55.52K 121.7K

Buyers (Bids)

No. Vol. Price($)
2 33067 45.0¢
 

Sellers (Offers)

Price($) Vol. No.
47.0¢ 20000 1
View Market Depth
Last trade - 15.48pm 03/12/2024 (20 minute delay) ?
Last
46.5¢ 		  Change
0.035 ( 5.68 %)
Open High Low Volume
45.0¢ 46.5¢ 45.0¢ 48153
Last updated 15.48pm 03/12/2024 ?
RCE (ASX) Chart

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Breaking news: New opportunities for investors & companies - HotCopper opens to capital raising! Companies can now raise capital through HotCopper! It’s a development allowing a highly cost-effective service to ASX-listed companies, while opening new investment opportunities to investors.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.